Results 61 to 70 of about 326,443 (336)
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Medical Journal of BabylonBackground: Urothelial carcinoma (UC) has been considered the most frequent bladder tumor. Although the degree of bladder wall invasion and grade of the tumor are the essential prognostic factors in bladder carcinoma, there is no dependable parameter ...
Khalid W. Abdulfattah Khattab +2 more
doaj +1 more source
Synergistic Antitumor Activity and Mechanism of Lapatinib and Paclitaxel in Esophageal Cancer Cells
Zhongliu Fangzhi Yanjiu, 2021 Objective To investigate the anti-tumor activity and mechanism of lapatinib, paclitaxel and their combination on esophageal cancer cells EC109. Methods MTT assay was used to detect the effects of lapatinib (1, 2, 4, 8 μmol/L), paclitaxel (5, 10, 20, 40 ...
CHEN Tao, LI Xiongwei, SUN Xiaodong
doaj +1 more source
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade [PDF]
JNCI: Journal of the National Cancer Institute, 2019 Abstract Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with ...
Aleix Prat +34 more
openaire +7 more sources
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
OncoImmunology, 2017 Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies.
Takuya Osada +12 more
doaj +1 more source
FEBS Open Bio, EarlyView.Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source
Cancer Biology & Medicine, 2022 Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with the emergence of oncogene targeted therapies, treatment options have tremendously improved. Owing to their biological relevance, members of the ERBB receptor family,
Tobias Boch +3 more
doaj +1 more source
Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. [PDF]
, 2013 IntroductionYoung women have poorer survival after breast cancer than do older women. It is unclear whether this survival difference relates to the unique distribution of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-defined ...
Clarke, Christina A +6 more
core +2 more sources
The Serine/Threonine Protein Kinase (Akt)/ Protein Kinase B (PkB) Signaling Pathway in Breast Cancer [PDF]
, 2020 According to statistical data published in 2019, breast cancer is among the leading causes of death in women worldwide. The serine/threonine kinase (AKT) or protein kinase B (PkB) signaling pathway is activated by phosphorylation processes, which further
Bratu, Ovidiu Gabriel +8 more
core +3 more sources